World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
63
Citations
47838
World Ranking
9941
National Ranking
4349

Overview

Gerald P. Linette is affiliated with the University of Pennsylvania in the United States and has a research focus primarily within the fields of Medicine and Immunology and Microbiology. Their work extensively covers subfields such as Oncology, Immunology, and Molecular Biology, with additional contributions in Electrical and Electronic Engineering and Epidemiology.

The scientist's research centers around several main topics, including:

  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Cancer Immunotherapy and Biomarkers
  • Immune Cell Function and Interaction
  • T-cell and B-cell Immunology
  • Polyomavirus and related diseases
  • Viral Infectious Diseases and Gene Expression in Insects

Gerald P. Linette has published multiple recent papers reflecting these themes. Some notable publications include:

  • Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial, 2021, The Lancet Oncology
  • Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial, 2020, Journal for ImmunoTherapy of Cancer
  • Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting, 2021, Nature Communications
  • Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma, 2023, Cancer Research Communications
  • Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial, 2021, The Lancet Oncology

The scientist collaborates frequently with several coauthors, including:

  • Beatriz M. Carreno
  • Adham S. Bear
  • Tatiana Blanchard
  • Robert H. Vonderheide
  • Chong Xu

Gerald P. Linette's work is published primarily in venues such as the Journal for ImmunoTherapy of Cancer, Regular and Young Investigator Award Abstracts, Cancer Research, The Lancet Oncology, and Cancer Cell. These journals reflect the medical and immunological focus of their research.

Best Publications

  • Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.

    F. Stephen Hodi;Steven J. O'Day;David F. McDermott;Robert W. Weber

  • Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

    Michael A. Postow;Jason Chesney;Anna C. Pavlick;Caroline Robert

  • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

    Jeffrey S Weber;Sandra P D'Angelo;David Minor;F Stephen Hodi

  • Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

    Robert H.I. Andtbacka;Howard L. Kaufman;Frances Collichio;Thomas Amatruda

  • A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells

    Beatriz M. Carreno;Vincent Magrini;Michelle Becker-Hapak;Saghar Kaabinejadian

  • Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

    Jedd D Wolchok;Bart Neyns;Gerald Linette;Sylvie Negrier

  • Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

    Gerald P. Linette;Edward A. Stadtmauer;Marcela V. Maus;Aaron P. Rapoport

  • Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

    Howard L. Kaufman;Jeffery Russell;Omid Hamid;Shailender Bhatia

  • Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

    F Stephen Hodi;Jason Chesney;Anna C Pavlick;Caroline Robert

  • The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy

    Jeffrey S. Ross;Jeffrey S. Ross;Jonathan A. Fletcher;Gerald P. Linette;Gerald P. Linette;James Stec

  • Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

    Antoni Ribas;Richard Kefford;Margaret A. Marshall;Cornelis J.A. Punt

  • Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells

    Brian J. Cameron;Andrew B. Gerry;Joseph Dukes;Jane V. Harper

  • A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

    Alexander C. Huang;Robert J. Orlowski;Robert J. Orlowski;Xiaowei Xu;Rosemarie Mick

  • Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

    James Larkin;David Minor;Sandra D'Angelo;Bart Neyns

  • Bcl-XL and Bcl-2 repress a common pathway of cell death.

    Debra T. Chao;Gerald P. Linette;Lawrence H. Boise;Lynn S. White

  • Targeted Therapy in Breast Cancer The HER-2/neu Gene and Protein

    Jeffrey S. Ross;Jeffrey S. Ross;Jonathan A. Fletcher;Kenneth J. Bloom;Gerald P. Linette;Gerald P. Linette

  • Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation

    Gerald P. Linette;Ying Li;Kevin Roth;Stanley J. Korsmeyer

  • Targeted therapies for cancer 2004.

    Jeffrey S. Ross;Jeffrey S. Ross;David P. Schenkein;Robert Pietrusko;Mark Rolfe

  • pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens.

    Jasreet Hundal;Beatriz M. Carreno;Allegra A. Petti;Gerald P. Linette

  • Reactive oxygen species and the regulation of cell death by the Bcl-2 gene family

    Stanley J. Korsmeyer;Xiao Ming Yin;Zoltán N. Oltvai;Deborah J. Veis-Novack

Frequent Co-Authors

Omid Hamid
Omid Hamid Cedars-Sinai Medical Center
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Céleste Lebbé
Céleste Lebbé Hôpitaux Universitaires Paris-Ouest
F. Stephen Hodi
F. Stephen Hodi Harvard University
Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University
Jeffrey S. Ross
Jeffrey S. Ross Foundation Medicine
Michele Milella
Michele Milella University of Verona
Jason Chesney
Jason Chesney University of Louisville
Caroline Robert
Caroline Robert University of Paris-Saclay

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Biology or Biochemistry can open doors to many diverse career opportunities, especially when combined with specialized online degrees. For example, health information management is a fast-growing field, and earning a him degree prepares graduates for roles in organizing and securing patient health data.

Many biochemistry and biology students also gravitate towards health technology and data roles, such as becoming a medical coder. If you're curious about this career, you may wonder how much do medical coders make or whether is medical coding a dying career. Exploring these questions can help you make informed career choices.

For those interested in health and wellness, an online master's degree in nutrition can lead to exciting positions in clinical nutrition, food science, or research. With flexible online degree options, you can tailor your studies to match your interests and the evolving job market.

Best Scientists Citing Gerald P. Linette

Trending Scientists

Recently Published Articles